Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery

Summary

We investigated the relationship between factor XIII, fibrinogen, blood coagulation screening tests and postoperative bleeding in 98 patients undergoing cardiopulmonary bypass (CPB) surgery. All patients received aprotinin. Blood samples were collected preoperatively (T1), after termination of CPB (T2), 12 h (T3) and 24 h (T4) after surgery to determine FXIII activity, fibrinogen, platelet count, prothrombin time (PT), activated partial thromboplastin time (APTT) and D-dimers (DD). Laboratory results were correlated with the chest tube drainage 24 h after surgery and compared between patients with 24-hour chest tube drain volumes in the lower (Group 1) with those in the upper tertile (Group 3). Median FXIII and fibrinogen levels dropped by 33.9% and 34.2%, respectively, during CPB. No association between FXIII activity and the extent of postoperative bleeding was found. However, chest tube bleeding was significantly correlated with preoperative and postoperative fibrinogen. This was confirmed by comparing Groups 1 and 3. Group 3 patients had significantly lower fibrinogen levels than Group 1 at T1 – T4, although most fibrinogen values were within or above the reference range (medians, g/l: 3.5 vs. 4.0, p = 0.043 at T1; 2.3 vs. 2.7, p = 0.015 at T2; 2.9 vs. 3.3, p = 0.008 at T3; 4.2 vs. 5.2, p = 0.002 at T4). There was also a significant relationship of platelet count, PT and APTT, as measured after CPB (T2), with postoperative chest tube drainage. In conclusion, plasma FXIII activity does not influence postoperative bleeding in patients undergoing CPB surgery. There is however an inverse association between preoperative or postoperative plasma fibrinogen levels and postoperative bleeding. These findings indicate a modulation of postoperative bleeding by fibrinogen levels.

Keywords

Cardiopulmonary bypass surgery - postoperative bleeding - factor XIII - fibrinogen - haemostasis screening tests

• References

• 1 Karkouti K, Wijeysundera DN, Yau TM. et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004; 44: 1453-62.
• 2 Despotis GJ, Skubas NJ, Goodnough LT. Optimal management of bleeding and transfusion in patients undergoing cardiac surgery. Semin Thorac Cardiovasc Surg 1999; 11: 84-104.
• 3 Hyde JA, Chinn JA, Graham TR. Platelets and cardiopulmonary bypass. Perfusion 1998; 13: 389-407.
• 4 Khuri SF, Chinn AD, Valeri CR. The effect of cardiopulmonary bypass on hemostasis and coagulation. In: Loscalzo J, Schafer AI, eds. Thrombosis and Hemorrhage. 1998. Cambridge, MA: Blackwell Scientific;
• 5 Shainoff JR, Estafanous FG, Yared JP. et al. Low factor XIIIA levels are associated with increased blood loss after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994; 108: 437-45.
• 6 Gödje O, Haushofer M, Lamm P. et al. The effect of factor XIII on bleeding in coronary surgery. Thorac Cardiovasc Surg 1998; 46: 263-67.
• 7 Chandler WL, Patel MA, Gravelle L. et al. Factor XIIIA and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis 2001; 12: 101-8.
• 8 Essell JH, Martin TJ, Salinas J. et al. Comparison of thrombelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993; 7: 410-15.
• 9 Despotis GJ, Grishaber JE, Goodnough LT. et al. The effect of an intraoperative treatment algorithm on physicians´ transfusion practice in cardiac surgery. Transfusion 1994; 34: 290-6.
• 10 Gelb AB, Roth I R, Levin J. et al. Changes in blood coagulation during and following cardiopulmonary bypass. Am J Clin Pathol 1996; 106: 87-99.
• 11 Nuttall GA, Oliver WC, Ereth MH. et al. Coagulation tests predict bleeding after cardiopulmonary bypass. J Cardiothor Vasc Anesth 1997; 11: 815-23.
• 12 American Society of Anesthesiologists Task Force on Blood Component Therapy. Practice guidelines for blood component therapy. Anesthesiology 1996; 84: 732-47.
• 13 Fickenscher K, Aab A, Stueber W. A photometric assay for blood coagulation factor XIII. Thromb Haemost 1001; 65: 535-40.
• 14 Hellstern P, Muntean W, Schramm W. et al. Practical guidelines for the clinical use of plasma. Thromb Res 2002; 107: S53-S57.
• 15 Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks?. Ann Intern Med 1999; 130: 933-7.
• 16 Bevan DH. Cardiac bypass haemostasis: putting blood through the mill. Br J Haematol 1999; 104: 208-19.
• 17 Gravlee GP, Arora S, Lavender SW. et al. Predictive value of blood clotting tests in cardiac surgical patients. Ann Thorac Surg 1994; 58: 216-21.
• 18 Ti LK, Cheong KF, Chen FG. Prediction of excessive bleeding after coronary artery bypass graft surgery: the influence of timing and heparinase on thrombelastography. J Cardiothorac Vasc Anesth 2002; 16: 545-50.
• 19 Fassin W, Himpe D, Alexander JP. et al. Predictive value of coagulation testing in cardiopulmonary bypass surgery. Acta Anesth Belg 1991; 42: 191-8.
• 20 Dorman BH, Spinale FG, Bailey MK. et al. Identification of patients at risk for excessive blood loss during coronary artery bypass surgery: thrombelastography versus coagulation screen. Anesth Analg 1993; 76: 694-700.
• 21 Ereth MH, Nuttall GA, Klindworth JT. et al. Does the platelet-activated clotting test (HemoSTATUS) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass?. Anesth Analg 1997; 85: 259-64.
• 22 Ereth MH, Nuttall GA, Santrach PJ. et al. The relation between the platelet-activated clotting test (HemoSTATUS) and blood loss after cardiopulmonary bypass. Anesthesiology 1998; 88: 962-9.